Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
JAMA · 18.03.2025 · 333 (11) · 972
DOI: 10.1001/jama.2024.26698 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 18.03.2025. Verfasst von E Shelley Hwang und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University, Durham, North Carolina. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Watchful Waiting. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown.
Objective
To compare rates of invasive cancer in patients with low-risk DCIS receiving active monitoring vs guideline-concordant care. Design, Setting, and Participants Prospective, randomized noninferiority trial enrolling 995 women aged 40 years or older with a new diagnosis of hormone receptor–positive grade 1 or grade 2 DCIS without invasive cancer at 100 US Alliance Cancer Cooperative Group clinical trial sites from 2017 to 2023.
Interventions
Participants were randomized to receive active monitoring (follow-up every 6 months with breast imaging and physical examination; n = 484) or guideline-concordant care (surgery with or without radiation therapy; n = 473). Main Outcomes and Measures The primary outcome was 2-year cumulative risk of ipsilateral invasive cancer diagnosis, according to planned intention-to-treat and per-protocol analyses, with a noninferiority bound of 5%.
Results
The median age of the 957 participants analyzed was 63.6 (95% CI, 55.5-70.5) years in the guideline-concordant care group and 63.7 (95% CI, 60.0-71.6) years in the active monitoring group. Overall, 15.7% of participants were Black and 75.0% were White. In this prespecified primary analysis, median follow-up was 36.9 months; 346 patients had surgery for DCIS, 264 in the guideline-concordant care group and 82 in the active monitoring group. Forty-six women were diagnosed with invasive cancer, 19 in the active monitoring group and 27 in the guideline-concordant care group. The 2-year Kaplan-Meier cumulative rate of ipsilateral invasive cancer was 4.2% in the active monitoring group vs 5.9% in the guideline-concordant care group, a difference of −1.7% (upper limit of the 95% CI, 0.95%), indicating that active monitoring is not inferior to guideline-concordant care. Invasive tumor characteristics did not differ significantly between groups. Conclusions and Relevance Women with low-risk DCIS randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care. Trial Registration ClinicalTrials.gov Identifier: NCT02926911
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Duke University, Durham, North Carolina.
- Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
- Departments of Population Health Sciences and Mathematics, Duke University, Durham, North Carolina.
- Department of Surgery/Oncology, University of Rochester, Rochester, New York.
- Alliance Foundation Trials, Boston, Massachusetts.
- Aurora Health Care, Milwaukee, Wisconsin.
Förderung
- NCI NIH HHS
Zitieren
APA
Hwang, E. S., Hyslop, T., Lynch, T., Ryser, M. D., Weiss, A., Wolf, A., Norris, K., Witten, M., Grimm, L., Schnitt, S., Badve, S., Factor, R., Frank, E., Collyar, D., Basila, D., Pinto, D., Watson, M. A., West, R., Davies, L., …, & COMET Study Investigators (2025). Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ. JAMA, 333(11), 972. https://doi.org/10.1001/jama.2024.26698
Vancouver
Hwang ES, Hyslop T, Lynch T, Ryser MD, Weiss A, Wolf A, et al. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ. JAMA. 2025;333(11):972. doi:10.1001/jama.2024.26698
BibTeX
@article{Hwang2025,
author = {Hwang, E Shelley and Hyslop, Terry and Lynch, Thomas and Ryser, Marc D and Weiss, Anna and Wolf, Anna and Norris, Kelsey and Witten, Meredith and Grimm, Lars and Schnitt, Stuart and Badve, Sunil and Factor, Rachel and Frank, Elizabeth and Collyar, Deborah and Basila, Desiree and Pinto, Donna and Watson, Mark A and West, Robert and Davies, Louise and Donovan, Jenny L and Shimada, Ayako and Li, Yutong and Li, Yan and Bennett, Antonia V and Rosenberg, Shoshana and Marks, Jeffrey and Winer, Eric and Boisvert, Marc and Giuliano, Armando and Larson, Kelsey E and Yost, Kathleen and McAuliffe, Priscilla F and Krie, Amy and Tamirisa, Nina and Carey, Lisa A and Thompson, Alastair M and Partridge, Ann H and COMET Study Investigators, COMET Study Investigators},
title = {Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ},
journal = {JAMA},
year = {2025},
volume = {333},
number = {11},
pages = {972},
doi = {10.1001/jama.2024.26698}
}
EUVIMED